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Abstract: The aim is to conduct a descriptive, population-based study in order to assess temporal
and spatial changes in mortality due to granulomatosis with polyangiitis (GPA) in Spain from 1984
to 2016. Mortality data were obtained from the Spanish Annual Death Registry. Deaths in which
GPA was the underlying cause were selected using the 446.4 and M31.3 codes from the International
Classification of Diseases, 9th and 10th revision. Annual average age at death and age-adjusted
mortality rates were calculated. Geographic analysis was performed at municipality and district level.
Variations in mortality according to the type of municipality (urban, agro-urban or rural), district and
geographic location (degrees of latitude) were assessed using standardized mortality ratios (SMRs)
and smoothed-SMRs. Over the whole period, 620 deaths due to GPA were identified. Age at death
increased at an average annual rate of 0.78% over the period 1987–2016 (p < 0.05). Age-adjusted
mortality rates increased by an annual average of 20.58% from 1984 to 1992, after which they fell by
1.91% a year (p < 0.05). The agro-urban category had the highest percentage (4.57%) of municipalities
with a significantly higher GPA mortality rate than expected. Geographic analysis revealed four
districts with a higher risk of death due to GPA, two in the North of Spain and two in the South.
This population-based study revealed an increase in the age at death attributed to GPA. Age-adjusted
mortality rates went up sharply until 1992, after which they started to decline until the end of the
study period. Geographic differences in mortality risk were identified but further studies will be
necessary to ascertain the reasons for the distribution of GPA disease.
Keywords: mortality; Spain; granulomatosis with polyangiitis; geographic patterns; temporal trends;
latitude; mapping; Wegener
1. Introduction
Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s Granulomatosis, is a
systemic necrotizing vasculitis characterized primarily by a granulomatous inflammation of small
and medium vessels [1]. It typically affects the respiratory tract and kidneys leading to premature
death if not treated [2]. It is considered a rare disease due to its low prevalence (less than five cases per
10,000 inhabitants) and its etiology remains unknown [3–5].
Mortality due to GPA is still high, especially in the first year after diagnosis, despite better
treatments being available [6]. Although the death rate amongst GPA patients has been reduced since
the beginning of the 21st century, it remains higher than the mortality in the general population [7].
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Age at death is increasing amongst patients suffering from this rare disease due to improvement in
treatments based on cyclophosphamide, glucocorticoids and rituximab [8,9].
The incidence of GPA at an international level has been increasing since the 1980s and then stabilized
in the early 2000s, suggesting an increasing physician awareness following the introduction of routine
anti-neutrophil cytoplasmic antibodies (ANCAs) testing [10]. Furthermore, there are considerable
variations between the incidence rates in different countries [2]. In Europe, notwithstanding the fact
that there are variations in methodology in the different studies, data suggest that the incidence of
this disease is two to four times greater in northern than in southern countries. Previous researchers
reported an annual incidence rate of 9.8 (95% CI = 7.4–12.2) per million people in Sweden, 9.3 (8.1–10.6)
in Finland, 11.8 (10.7–12.9) in United Kingdom, and 7.7 (4.1–11.4) in Poland, indicating a possible
spatial variation in incidence rates [11–14]. In Spain, epidemiological information about GPA is still
scarce and there are no studies of mortality or other indicators at a national level. The little research so
far conducted on this subject has focused on incidence rates at a provincial or local level. These studies
found that Lugo province had an annual rate of 2.95 cases per million inhabitants, the city of Sabadell
in Barcelona province had 4.1 cases, while the rate in Málaga province was much lower at 2.1 cases per
million [15–17].
Geographic analyses of GPA in which populations are stratified into rural and urban areas have
been conducted in several European regions and in parts of Australia [11,17–19]. These investigations
sought to assess the differences between the incidence or prevalence of GPA in rural and urban
areas. In the case of Lugo province (Spain), for example, there was higher incidence in urban areas.
Several studies have also analyzed GPA by comparing incidence rates in Europe according to latitude.
These found higher rates in northern than in southern European countries [20]. At a Spanish level,
we thought it might be interesting therefore to observe the variation in mortality rates according to
latitude, based on the assumption that northern regions will have higher rates than southern ones.
In view of the paucity of national population-based data, this study also seeks to analyze mortality
due to GPA in Spain over a long period. The objectives were to: (1) evaluate the time trends in GPA
mortality over a 32-year period; and (2) analyze the geographical distribution of mortality at municipal
and district level, in rural vs. urban areas and according to latitude.
2. Materials and Methods
This research focuses on the trend over time and the geographic distribution of GPA mortality for
the period 1984–2016. Mortality data were obtained from the Spanish Annual Death Registry kept by
the Spanish National Statistics Institute (NSI) (Instituto Nacional de Estadística). GPA as underlying
cause of each death is noted by the codes 446.4 in the International Classification of Diseases (ICD) 9th
edition (period 1984 and 1998), and M31.3 in the ICD 10th edition (period 1999–2016). Underlying
cause of death is defined by the World Health Organization as “the disease or injury which initiated the
train of morbid events leading directly to death, or the circumstances of the accident or violence which
produced the fatal injury” [21]. Population data were also obtained from the NSI and categorized by
gender and age at municipal and district or comarca level (in Spanish the word “comarca” refers to an
area or territory that contains several towns and villages but is smaller than a region).
The age-adjusted mortality rates were calculated, using the European standard population as
reference, for males, females, and both sexes (expressed per 1,000,000 inhabitants). Annual trends were
smoothing using the TH4253 non-parametric procedure which uses running medians to summarize
overlapping segments in the time-series data leading to delete random movements [22]. Average age
at death and mortality trends were evaluated using joinpoint regression models to describe changes in
the time-series data where line segments are joined in the joinpoints [23].
In order to assess the variation in mortality in rural and urban areas, the Spanish municipalities
were broken down into three categories. Normally, municipalities are classified as rural or urban
according to population criteria [17,19]. However, this classification seems imprecise due to the varying
characteristics of municipalities in Spain. Northern municipalities are usually smaller in terms of
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population but have more industry, while Southern municipalities tend to have larger populations
and are economically more oriented towards the agricultural sector. We therefore decided to include
an intermediate category for those municipalities with both urban and rural characteristics using
not only population data but also the number of people working in the primary sector (PWPS),
which includes activities such as agriculture, livestock, mining or fishing. The data about the sectors
in which people are employed were provided by the NSI. On this basis, in this study we used the
following three categories:
(a) Urban: less than 5% PWPS
(b) Agro-urban: more than 5% PWPS and more than 10,000 inhabitants
(c) Rural: more than 5% PWPS and less than 10,000 inhabitants or labor force of less than 50 people.
To assess the variation in mortality according to latitude, Spain was divided into horizontal
strips of one degree of latitude. The most northerly strip was at 44◦ and the most southerly at 36◦.
The municipalities in the Canary Islands were grouped together under the same latitude strip (from
27◦ N to 29◦ N).
For disease mapping purposes, standardized mortality ratios (SMRs) were calculated by
municipality using the expected GPA mortality rate in Spain for the period 1999–2016 as a reference
(SMR = 1.00). Municipalities were previously divided into three categories as described above: urban,
agro-urban and rural areas. Similarly, SMRs were also calculated for groups of municipalities with the
same latitude in an attempt to uncover possible North-South variations in mortality.
The smoothing procedure for geographic units was carried out at comarca (district) level.
The smoothed-SMRs for the period 1999–2016 were calculated for district using the cases observed
in each district together with the expected cases, and taking the sex- and age-specific death rates for
the Spanish population as a reference. We used a conditional autoregressive model based on two
effects: unstructured spatial random effect and spatially structured heterogeneity [24]. As a measure of
uncertainty, the Posterior Probability (PP) of each district being above average risk was computed.
PP shows those districts with significantly higher (PP > 0.80) or lower (PP < 0.20) risks of death due to
GPA than that expected for the country as a whole.
The statistical analyses and the smoothing procedure were performed using the Stata and
R software respectively. The ArcGIS software program (Esri, Redlands, CA, USA) was used for
geographic analysis and cartographic representations.
3. Results
Overall, we identified 620 deaths from GPA over the period 1984–2016 in Spain, of which 55.5%
were males (Figure 1). The average age at death for GPA patients was 65.6 years ± 14.6 Standard
Deviation (STD); 65.2 years ± 14.6 STD in males; and 65.8 years ± 14.8 STD in females. GPA age at
death increased by 0.78% a year (annual percent change, APC) between 1987 and 2016 (p < 0.05).
By sexes, age at death increased annually by 0.61% in males and 0.74% in females over the whole study
period (1984–2016) (p < 0.05).
The overall age-adjusted mortality rate for the period was 0.35 (95% Confidence Interval (CI) =
0.32–0.38) per million inhabitants: 0.44 (95% CI = 0.39–0.49) in males, and 0.28 (95% CI = 0.24–0.32) in
females. Joinpoint analysis showed a 20.58% increase in the age-adjusted mortality rate between 1984
and 1992 (p < 0.001) and an annual fall of 1.91% from 1992 to 2016 (p < 0.001). Rates were higher for
males than for females, and there was a significant increase of 21.57% APC (p < 0.001) over the period
1984–1992. From then on, the rate declined (−2.13% APC; p < 0.001). In females, there was a significant
increase in the death rate of 36.1% APC (p < 0.001) from 1984 to 1989 after which it remained stable
over the rest of the period. These trends for both sexes (males and females) are similar to the smoothed
age-adjusted mortality rates and in the aggregation into intervals (Figure 2).
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municipality, 4.57% of agro-urban municipalities had a significantly higher GPA mortality than 
expected for Spain as a whole, while this percentage was lower in urban and rural municipalities 
(Table 1). Only one urban municipality obtained a death risk lower than expected (Barcelona: SMR = 
0.52; 95% CI = 0.24–0.98). However, global SMR in these categories was similar to the expected value 
(SMR = 1.00): SMRs due to GPA in all agro-urban areas considered as a whole were 1.25 (95% CI = 
0.93–1.64), 0.87 (95% CI = 0.68–1.10) in rural and 1.00 (95% CI = 0.89–1.12) in urban. 
  
Figure 2. Age-adjusted mortality rates due to GPA in males, females and both genders. (a) Annual
smooth d rates; (b) five-yea rates (except for 2014 to 2016), bars show 95% confidence intervals.
According to our classification of Spanish municipalities as urban, agro-urban or rural, 16.2% were
considered as urban, 2.7% s agro-urban and 81.1% as rural (Table 1). Deaths d e to GPA took place in
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271 municipalities (3.34% of the total of Spanish municipalities). According to SMR by municipality,
4.57% of agro-urban municipalities had a significantly higher GPA mortality than expected for Spain
as a whole, while this percentage was lower in urban and rural municipalities (Table 1). Only one
urban municipality obtained a death risk lower than expected (Barcelona: SMR = 0.52; 95% CI =
0.24–0.98). However, global SMR in these categories was similar to the expected value (SMR = 1.00):
SMRs due to GPA in all agro-urban areas considered as a whole were 1.25 (95% CI = 0.93–1.64), 0.87
(95% CI = 0.68–1.10) in rural and 1.00 (95% CI = 0.89–1.12) in urban.
Table 1. Distribution of municipalities categorized as urban, agro-urban or rural; number of deaths due
to GPA and municipalities with higher or lower GPA mortality than expected for Spain in 1999–2016














Urban 1316 (16.2%) 162 300 22 (1.67%) 1 (0.08%)
Agro-urban 219 (2.7%) 40 52 10 (4.57%) 0
Rural 6588 (81.1%) 69 71 25 (0.38%) 0
Throughout the Spanish territory, while urban municipalities are frequent along the Mediterranean
(Catalonia, Valencia) and Atlantic coasts (northern Spain) and in the center (around Madrid),
rural municipalities tend to be concentrated in inland Spain (Figure 3). Most agro-urban municipalities
are located in the South (Andalusia and Murcia). Agro-urban areas typically have a medium-sized
population and a relatively strong primary sector compared with other parts of Spain.
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Figure 3. Classification of urban, agro-urban and rural municipalities in Spain. Latitude bands
are shown.
According to SMR results for municipalities grouped within the same degree of latitude,
an increased death risk due to GPA can be observed not only in the far North of the Iberian Peninsula
but also in the South (degree 36◦ N and statistically significant: SMR = 1.79) for both sexes (Figure 3;
Table 2). The lowest death rate was in the 40◦ N strip (SMR = 0.75 and statistically significant),
which runs across the center of the Iberian Peninsula and includes the capital, Madrid. By sexes,
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SMR results showed a significantly higher death risk for males in the coastal areas of Andalusia in
southern Spain (36◦ N strip): SMR = 1.91; 95% CI = 1.29–2.72), however it was not significant for
women. In the southernmost latitude in Spain, the Canary Islands, there was a higher risk for both
sexes together and for women separately, however these results were not significant.
Table 2. Number of municipalities, deaths and standardized mortality ratio (SMR) results for each






Both Sexes Both Sexes Women
43◦ N 519 64 1.28 (0.99–1.63) 1.16 (0.79–1.63) 1.44 (0.99–2.04)
42◦ N 1842 50 1.05 (0.78–1.38) 1.26 (0.87–1.76) 0.77 (0.44–1.25)
41◦ N 2078 70 0.83 (0.65–1.05) 0.86 (0.62–1.17) 0.79 (0.53–1.13)
40◦ N 1507 52 0.75 (0.56–0.99) 0.73 (0.49–1.06) 0.79 (0.50–1.17)
39◦ N 795 40 0.90 (0.64–1.22) 0.91 (0.58–1.37) 0.88 (0.51–1.41)
38◦ N 579 37 0.97 (0.68–1.34) 1.00 (0.62–1.51) 0.93 (0.53–1.53)
37◦ N 500 41 0.88 (0.63–1.20) 0.80 (0.50–1.23) 0.99 (0.61–1.53)
36◦ N 215 49 1.79 (1.33–2.37) 1.91 (1.29–2.72) 1.64 (0.98–2.55)
27◦–29◦ N 88 20 1.28 (0.78–1.98) 0.87 (0.38–1.72) 1.84 (0.95–3.22)
Finally, in smoothed SMRs a similar pattern can be seen as the territory gradation according to
latitude: there are several areas in the North and in the South with a higher than expected death rate
while in the center there were several districts with lower than expected results (Figure 4). The lowest
death risks due to GPA were noted in some areas of western Galicia (Northwest) and in metropolitan
areas of Madrid and Barcelona. While of the four districts in Spain with a significantly higher risk of
death (PP > 0.80), two were in the North (one in Galicia and one in the Basque Country) and two were
in the South (Andalusia).
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4. Discussion
This retrospective epidemiological study on mortality due to GPA is the first of its kind in Spain
at a national level and over a long period. In this paper we offer a detailed description of geographic
variation in mortality rates from different perspectives so as to understand the spatial distribution of
this rare disease in Spain.
The annual increase we noted in the average age at death due to GPA is in step with a similar
study in England over the period 1992–2013 [25]. The increasing survival rate has been achieved
thanks to quicker diagnosis, which has enabled improved treatments to alleviate damage to affected
organs [9]. This has been achieved partly due to the introduction of blood tests for ANCAs, as positive
levels of ANCAs proteins are related to certain forms of systemic vasculitis such as GPA disease [26–29].
Better and faster diagnosis result in increased survival of the patients affected. Other authors reported an
improvement in the survival of GPA patients in recent decades associated with the use of less aggressive
therapies, so reducing other complications, although this depends on the organ affected [25,30].
We found that age-adjusted mortality rates have decreased significantly since 1992. In a nationwide
cohort of patients with end-stage renal disease due to GPA carried out in the United States, mortality
rates decreased dramatically between 1995 and 2014, reflecting an improvement in the management of
this disease over recent decades [31]. The change in the ICD code in 1999 (from the 9th to 10th edition)
does not seem to have affected the trends in GPA age-adjusted mortality rates in Spain. Nevertheless,
we do not know the impact of new clinical and molecular classifications for vasculitis on the ICD
coding of deaths due to GPA in Spain i.e., “Revised International Chapel Hill Consensus Conference
Nomenclature of Vasculitides 2012” [32]. Although our change in mortality time trend was detected
in 1992, long before this nomenclature revision for GPA, we cannot rule out some effect in our data.
An increase in these rates was observed in the population as a whole and in males until 1994 (the
opposite was observed in women), although from then on, the rate started to fall.
Variations in mortality in urban and rural areas could help to clarify whether GPA disease is
triggered by environmental factors. In a study comparing vasculitis diseases in Germany, there were
higher incidence rates in cities than in rural areas [19]. In a study of the northern province of
Lugo in Spain, GPA incidence was also higher in urban municipalities [17]. However, the results
of similar studies in other countries have not confirmed these trends [33,34]. In our study, almost
5% of agro-urban municipalities showed significantly higher GPA mortality than expected for Spain
as a whole, and this percentage was much lower in rural and urban municipalities. Agro-urban
municipalities are medium-sized municipalities in terms of population (average 21,500 inhabitants)
in which a substantial proportion of their citizens still work in the primary sector (more than 5%) in
activities such as agriculture and livestock farming. A case-control study on this question in Norfolk
(Eastern England) found a significant association between GPA and employment in farming [35].
In our study there is not sufficient ground to establish any positive association between farming in
rural areas and GPA given the very low proportion of rural municipalities with higher SMR than
expected. Our results are therefore not consistent with the findings obtained by Lane. Further studies
must be carried out in order to find out if there is any link between mortality and farming or perhaps
with the use of pesticides.
Several studies suggest that the incidence of GPA in Europe might follow a geographic pattern
and decreases from North to South [36,37]. This suggests that there is a higher chance of developing
GPA in northern countries perhaps due to environmental or genetic factors. Some authors highlight a
possible link with the sunlight protection factor (higher in Mediterranean countries) and the benefits of
Vitamin D [38]. The role of genetics in the incidence of GPA was also discussed by various authors,
particularly with regard to the more frequent presence of the PTPN22 R620W polymorphism in
northern European populations [39]. Another comparative study showed a higher incidence of this
disease in Northern Spain than in the south of the country [15]. In our study, mortality rates did not
follow any obvious latitude pattern, with higher rates in areas of both Northern and Southern Spain,
so coming to the same conclusions as observed in Germany in the period 1998–1999 [36]. In addition,
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latitude effect could be only noticeable at an international scale, such as European, and not in a single
country. It is also possible that a geographic pattern in Spain could have been weakened due to internal
migratory flows over the course of history [40].
When we analyzed the results for the different Spanish districts, no clear geographical North-South
pattern could be observed. Nor could we find any significant rural/urban differences. This suggests that
further, in-depth analysis is required to explain the geographic distribution of GPA in Spain. Family
grouping in GPA disease is infrequent except in cases of first-degree relatives, which would suggest
that the disease may have environmental causes [41]. Several studies point out that higher incidences
of systemic vasculitis might be associated with environmental factors, such as silica exposure [42,43].
However, everything suggests that GPA is a complex, multifactorial disease in which both genetics
and the environment play a role [20,35,44].
The present study has several limitations, such as the fact that our population-based death registry
does not provide personal information with regard to occupation, disease-related genetic history or
personal habits. For instance, a recent Spanish study found that GPA patients were more likely to have
a history of smoking than the population as a whole [45]. Findings like these make the relationship
between possible triggers for the disease and likely environmental factors increasingly difficult to
unravel. In addition, most GPA epidemiological studies focus on prevalence and incidence, which
makes it harder to compare mortality rates with other reports not only in Spain but also in other
countries. Our research consisted of a nationwide, population-based study over a long period of time
of the mortality directly attributed to GPA and followed a homogeneous, standardized methodology.
The increase in average age at death identified in our study is an important finding in that it allows
national or regional governments to plan the health services required to improve the life of GPA
patients more effectively. It is important to emphasize for example that the treatments for GPA disease
can be quite costly because patients often suffer relapses [46,47].
5. Conclusions
In conclusion, this study has analyzed deaths due to GPA in Spain over a 32-year period. Since 1992,
mortality rates have fallen and average age at death has increased due to better treatments and prompt
diagnosis. We found that areas categorized as agro-urban had a greater proportion of municipalities
with higher than expected mortality in comparison with urban and rural areas. We also analyzed
differences in death rates according to latitude, but no spatial pattern was found. More in-depth studies
are required to enable us to gain a better understanding of the etiology of GPA disease.
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